Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

4.9K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.9K
Functions of Thyroid Hormones01:18

Functions of Thyroid Hormones

3.0K
The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
3.0K
Drug Therapy01:28

Drug Therapy

90
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
90
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

339
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
339
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

40
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
40

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feminizing and masculinizing gender-affirming hormone therapy affects fibrin clot characteristics in opposite directions.

Research and practice in thrombosis and haemostasis·2026
Same author

Bone health in gender-diverse individuals: current challenges and future directions.

Hormones (Athens, Greece)·2026
Same author

Adsorption represents a critical challenge in the quantification of free 25-hydroxyvitamin D3.

Journal of molecular endocrinology·2026
Same author

Effects of gender-affirming hormone therapy from adolescence to adulthood on cardiovascular function: a cross-sectional study.

Frontiers in endocrinology·2026
Same author

Impact of testosterone-based gender-affirming hormone therapy on toll-like receptor transcript levels and peripheral blood leukocyte counts in transmasculine individuals.

Frontiers in immunology·2026
Same author

Cytokine Dynamics Following Initiation of Gender-Affirming Hormone Therapy in Transgender Subjects.

The Journal of clinical endocrinology and metabolism·2026

Related Experiment Video

Updated: Aug 26, 2025

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis
05:41

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Published on: February 9, 2024

715

Central hypothyroidism: are patients undertreated?

Joke Marlier1, Guy T'Sjoen1,2, Jean Kaufman1,2

  • 1Department of Endocrinology, Ghent University Hospital, Ghent, Belgium.

European Thyroid Journal
|October 7, 2022
PubMed
Summary

Patients with central hypothyroidism (CHT) experience worse quality of life (QoL) compared to primary hypothyroidism (PHT), despite similar levothyroxine doses. This suggests factors beyond hormone dosage impact well-being in CHT patients.

Keywords:
hormonal substitutionhypopituitarismhypothyroidismpituitarythyroid

More Related Videos

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model
04:14

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model

Published on: October 6, 2023

947
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.5K

Related Experiment Videos

Last Updated: Aug 26, 2025

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis
05:41

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Published on: February 9, 2024

715
Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model
04:14

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model

Published on: October 6, 2023

947
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.5K

Area of Science:

  • Endocrinology
  • Clinical Medicine
  • Patient Outcomes

Background:

  • Thyroid hormone replacement therapy is crucial for managing hypothyroidism.
  • Central hypothyroidism (CHT) presents unique challenges in thyroid hormone substitution compared to primary hypothyroidism (PHT).
  • Inappropriate thyroid hormone substitution can lead to suboptimal patient outcomes and reduced quality of life.

Purpose of the Study:

  • To compare levothyroxine dosage requirements between patients with CHT and PHT.
  • To evaluate and compare the quality of life (QoL) in patients with CHT versus PHT.
  • To investigate potential factors influencing QoL differences in these patient groups.

Main Methods:

  • A monocentric, cross-sectional study involving 82 patients (41 CHT, 41 PHT) at Ghent University Hospital.
  • Patients maintained stable levothyroxine doses for at least six months, with PHT patients achieving euthyroid status.
  • Quality of life was assessed using the SF-36 health score and the thyroid-specific ThyPRO questionnaire.

Main Results:

  • No significant differences were observed in age, BMI, total daily levothyroxine dose, or levothyroxine dose per kilogram body weight between CHT and PHT groups.
  • Serum free thyroxine (fT4) and free triiodothyronine (fT3) levels were comparable and within the normal range for both groups.
  • Patients with CHT reported significantly worse QoL, particularly in emotional symptoms, daily functioning, and social life, compared to PHT patients.

Conclusions:

  • A significant difference in quality of life exists between patients with central and primary hypothyroidism.
  • The observed QoL disparities in CHT patients are not explained by differences in levothyroxine dosage or thyroid hormone levels.
  • Further research is needed to identify the underlying causes of reduced QoL in central hypothyroidism and to optimize patient management.